Literature DB >> 30718036

Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis.

Ken Fukuda1, Waka Ishida2, Tatsuma Kishimoto2, Atsuki Fukushima2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30718036     DOI： 10.1016/j.alit.2018.12.012

Source DB:  PubMed          Journal:  Allergol Int        ISSN： 1323-8930            Impact factor:   5.836


× No keyword cloud information.
  6 in total

1.  Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae.

Authors:  Filippos Vingopoulos; Douglas R Lazzaro
Journal:  Int Med Case Rep J       Date:  2020-07-28

2.  Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.

Authors:  Mélanie Hébert; Susan Ruyu Qi; Eunice You; Mathieu Mercier; Patricia-Ann Laughrea
Journal:  BMJ Open Ophthalmol       Date:  2022-05

Review 3.  A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.

Authors:  Gaurav Agnihotri; Katherine Shi; Peter A Lio
Journal:  Drugs R D       Date:  2019-12

4.  Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.

Authors:  Rumi Adachi; Jun Shoji; Akira Hirota; Akiko Tomioka; Yukiko Tonozuka; Noriko Inada; Satoru Yamagami
Journal:  Allergy Asthma Clin Immunol       Date:  2022-10-02       Impact factor: 3.373

Review 5.  Atopic Dermatitis in Older Adults: A Review of Treatment Options.

Authors:  Ryoji Tanei
Journal:  Drugs Aging       Date:  2020-03       Impact factor: 3.923

6.  Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD),.

Authors:  Jodie Raffi; Raagini Suresh; Harvey Fishman; Nina Botto; Jenny E Murase
Journal:  Int J Womens Dermatol       Date:  2019-11-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.